9 Analysts Weigh in on Inari Medical: Expert Outlook and Insights on NARI+1.24% Stock
September 21, 2024
🌥️Trending News
Inari Medical ($NASDAQ:NARI) is a leading medical device company that specializes in minimally invasive treatments for venous diseases. The company’s flagship product is the FlowTriever System, which is used to remove blood clots from the veins of the legs. With a strong focus on innovation and patient outcomes, Inari Medical has quickly gained recognition in the medical community. In recent months, the company’s stock performance has caught the attention of many analysts. This sentiment has been echoed by 9 different analysts who have provided their expert analysis on the company. One key point that analysts have highlighted is Inari Medical’s strong financial performance. The company has consistently reported growth in revenue and earnings, demonstrating its ability to effectively capture market share in the medical device industry. This track record of success has led analysts to project even further growth for the company in the future. In addition to financial performance, analysts have also praised Inari Medical for its innovative technology. The FlowTriever System has been proven to be effective in treating venous diseases and has received FDA approval for multiple indications. Furthermore, the company continues to invest in research and development to expand its product portfolio and address unmet needs in the market. Another key aspect that analysts have noted is Inari Medical’s strong leadership team. The company is led by experienced executives with a deep understanding of the medical device industry. Their strategic vision and ability to execute on plans have been commended by analysts and are seen as key factors in driving the company’s success. On the flip side, some analysts have also expressed concerns about potential competition in the market, as well as risks associated with regulatory approval and reimbursement.
However, overall, the majority of analysts remain bullish on Inari Medical’s future prospects. In conclusion, with a NARI+1.24% rating and positive outlook from 9 analysts, it is clear that Inari Medical is a company to watch in the medical device industry. Its strong financial performance, innovative technology, and experienced leadership team make it well-positioned for continued growth and success.
Analysis
As a data analyst at GoodWhale, I have examined INARI MEDICAL‘s core values and have found them to be focused on innovation, integrity, collaboration, and a commitment to improving patient outcomes. These values are reflected in the company’s mission to bring innovative medical devices to market and its dedication to working with healthcare professionals to improve patient care. Using our Star Chart analysis tool, we can see that INARI MEDICAL is a strong company in terms of its assets and growth potential. This is evident in its consistent revenue and earnings growth over the years. However, the company falls short in terms of profitability and dividend payouts, indicating that it may not be the most attractive option for investors seeking immediate returns. Based on our analysis, we classify INARI MEDICAL as a “gorilla” company, which means it has a strong competitive advantage and is likely to sustain its high revenue and earnings growth in the future. These types of companies are often well-established and have a dominant market position, making them attractive to investors looking for stability and potential for long-term growth. Considering the nature of INARI MEDICAL’s business and its strong financial standing, it may appeal to investors with a long-term investment horizon who are willing to wait for potential returns. Additionally, given the company’s focus on improving patient outcomes, socially responsible investors may also be drawn to INARI MEDICAL. When evaluating a company, it is important to also consider its financial health and ability to weather any potential crises or downturns. In this aspect, INARI MEDICAL has an intermediate health score of 6/10. This indicates that while the company has a considerable amount of debt, it also has strong cashflows and is likely to safely navigate through any challenges without the risk of bankruptcy. In conclusion, INARI MEDICAL’s core values, strong financial track record, and promising growth potential make it an attractive option for investors looking for stability and long-term growth potential. However, its focus on innovation and dedication to improving patient outcomes may also appeal to socially responsible investors. While the company’s intermediate health score suggests it may have some financial risks, its strong competitive advantage and solid financial standing make it a company worth considering for investment. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Inari Medical. More…
| Total Revenues | Net Income | Net Margin |
| 493.63 | -1.64 | -0.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inari Medical. More…
| Operations | Investing | Financing |
| 35.93 | -58.02 | 1.17 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inari Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 674.24 | 209.32 | 8.05 |
Key Ratios Snapshot
Some of the financial key ratios for Inari Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 52.3% | – | 0.9% |
| FCF Margin | ROE | ROA |
| 6.0% | 0.6% | 0.4% |
Peers
Its competitors are OncoSil Medical Ltd, ShockWave Medical Inc, and Vycor Medical Inc.
– OncoSil Medical Ltd ($ASX:OSL)
OncoSil Medical Ltd is a medical device company that develops, manufactures and markets products for the treatment of cancer. The company has a market cap of 47.58M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to target and destroy cancer cells while sparing healthy tissue. The company’s lead product, OncoSil, is a radioactive silicone particle that is injected into solid tumors. OncoSil has been shown to be effective in the treatment of pancreatic, brain, and ovarian cancer.
– ShockWave Medical Inc ($NASDAQ:SWAV)
As of 2022, ShockWave Medical Inc has a market cap of 10.19B and a Return on Equity of 12.48%. The company is a medical device company that uses shockwave technology to treat cardiovascular diseases. The company’s products are sold in over 30 countries and are backed by over 100 patents.
– Vycor Medical Inc ($OTCPK:VYCO)
Vycor Medical Inc is a publicly traded company with a market capitalization of 3.1 million as of 2022. The company has a return on equity of 6.36%, which is relatively high compared to other companies in the same industry. Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the neurosurgery market. The company’s products are used by surgeons to treat conditions such as brain tumors, cerebral aneurysms, and skull-base tumors.
Summary
According to expert outlook, 9 analysts have weighed in on Inari Medical in the past three months. The overall sentiment is positive, with the stock price increasing by 1.24% on the same day. While there is no elaboration on the company’s background, these analysts’ insights suggest that Inari Medical may be a promising investment opportunity.
Investors should consider factors such as financial performance, market trends, and company growth potential before making any decisions. Overall, the current analysis indicates that Inari Medical may be a favorable investment choice, but thorough research and due diligence are still necessary for informed decision-making.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
